Floatz logo

Ladiratuzumab Vedotin

Hormone Receptor Positive Tumor

QuantumLeap Healthcare Collaborativeantibody_drug_conjugatePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

91 Active assets in the Hormone Receptor Positive Tumor cohort.

Asset / SponsorPhaseRating
FULVESTRANT
Relay Therapeutics, Inc.
Phase 3BB
Abemaciclib
Relay Therapeutics, Inc.
Phase 2BB
Letrozole
Relay Therapeutics, Inc.
Phase 2BB
Ribociclib
Relay Therapeutics, Inc.
Phase 3BB
Palbociclib
Relay Therapeutics, Inc.
Phase 2BB

View all 50 →

Same molecule, other indications

Ladiratuzumab Vedotin is also rated in:

triple-negative breast carcinomaDormant
BB
Indicative ·
65 / 100
View asset →
HER2 positive breast carcinomaDormant
B
Indicative ·
59 / 100
View asset →
angiosarcomaDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →